Ontology highlight
ABSTRACT: Purpose
Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone. However, only approximately 40% of such patients typically proceed to HCT.Methods
We used a prospective organized approach to rapidly identify donors to improve the allogeneic HCT rate in adults with high-risk acute myeloid leukemia in CR1. Newly diagnosed patients had cytogenetics obtained at enrollment, and those with high-risk cytogenetics underwent expedited HLA typing and were encouraged to be referred for consultation with a transplantation team with the goal of conducting an allogeneic HCT in CR1.Results
Of 738 eligible patients (median age, 49 years; range, 18-60 years of age), 159 (22%) had high-risk cytogenetics and 107 of these patients (67%) achieved CR1. Seventy (65%) of the high-risk patients underwent transplantation in CR1 (P < .001 compared with the historical rate of 40%). Median time to HCT from CR1 was 77 days (range, 20-356 days). In landmark analysis, overall survival (OS) among patients who underwent transplantation was significantly better compared with that of patients who did not undergo transplantation (2-year OS, 48% v 35%, respectively [P = .031]). Median relapse-free survival after transplantation in the high-risk cohort who underwent transplantation in CR1 (n = 70) was 11.5 months (range, 4-47 months), and median OS after transplantation was 14 months (range, 4-44 months).Conclusion
Early cytogenetic testing with an organized effort to identify a suitable allogeneic HCT donor led to a CR1 transplantation rate of 65% in the high-risk group, which, in turn, led to an improvement in OS when compared with the OS of patients who did not undergo transplantation.
SUBMITTER: Pagel JM
PROVIDER: S-EPMC7291544 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
Pagel John M JM Othus Megan M Garcia-Manero Guillermo G Fang Min M Radich Jerald P JP Rizzieri David A DA Marcucci Guido G Strickland Stephen A SA Litzow Mark R MR Savoie M Lynn ML Spellman Stephen R SR Confer Dennis L DL Chell Jeffrey W JW Brown Maria M Medeiros Bruno C BC Sekeres Mikkael A MA Lin Tara L TL Uy Geoffrey L GL Powell Bayard L BL Bayer Ruthee-Lu RL Larson Richard A RA Stone Richard M RM Claxton David D Essell James J Luger Selina M SM Mohan Sanjay R SR Moseley Anna A Erba Harry P HP Appelbaum Frederick R FR
JCO oncology practice 20200127 6
<h4>Purpose</h4>Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone. However, only approximately 40% of such patients typically proceed to HCT.<h4>Methods</h4>We used a prospective organized approach to rapidly identify donors to improve the allogeneic HCT rate in adults with high-risk acute myeloid leukemia in C ...[more]